Patients Stopping Anti-Obesity Medications Put On Weight at a Quadrupled Rate Compared to Dieters

Fresh analysis indicates that people who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional lifestyle regimens.

Published data in a major medical journal shows that while obese people can lose about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.

"People purchasing such treatments must be cognizant of the danger of fast rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.

That rate of regain suggests a reversion to starting weight in about a year and a half.

Comparing Therapies

The analysis, which reviewed 37 of trials involving over 9,000 of patients, contrasted the outcomes of the injectable medications with older methods.

Researchers note that individuals who lose weight through dieting typically have a less rapid creep back—approximately 0.1 kg a month—once they finish.

Understanding the Rapid Regain

Experts believe the mechanism of the jabs accounts for the accelerated regain.

GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.

"Artificially providing GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication leads to hunger is no longer kept in check, making excessive eating far more likely."

An Ongoing Issue?

Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.

A number of clinicians say that, considering the significant potential of relapse, the therapy might need to be life-long.

This opinion is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent nature of obesity," similar to managing conditions like diabetes.

Patient Experiences

People who have come off the medication explain a powerful resurgence of appetite.

"I experienced a switch activating and you're instantly ravenous," recalled one woman.

This difficulty is exacerbated if patients have not adopted permanent dietary or behavioural modifications during therapy.

Growing Adoption

Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.

• Use is greater among females than males.
• The 40s and 50s age group shows the highest usage rates.
• Many obtain the drugs through private healthcare rather than public health services.

Finally, researchers emphasize that while the jabs are potent agents for weight loss, they are not a permanent cure and long-term success likely depends on combined behavioural changes.